Ocrelizumab for the treatment of relapsing remitting multiple sclerosis: A cost effectiveness study in Peru
Preprint
- 29 June 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: This study examines the cost-effectiveness of Ocrelizumab, a treatment for relapsing-remitting multiple sclerosis (RRMS), in the Peruvian healthcare system. RRMS is a chronic autoimmune disease affecting the central nervous system, and its prevalence in Peru has been reported to be 9.12 cases per 100,000 inhabitants. Methods: A cohort multi-state Markov model was developed to simulate disease progression and evaluate the cost-effectiveness of Ocrelizumab compared to other treatment alternatives for RRMS. The model considered various health states, including relapse, disability progression, conversion to secondary-progressive MS, mortality, treatment effect waning, treatment withdrawal, and adverse events. Costs associated with medication, administration, monitoring, and adverse events were included. Quality-adjusted life years (QALYs) and life years (LYs) gained were analyzed using the EQ-5D-5L questionnaire. Results: In the base-case scenario, Ocrelizumab was found to be a cost-effective intervention, with a cost per QALY and LYs below the willingness-to-pay threshold. When compared to other treatment alternatives, Ocrelizumab was dominant, providing greater QALYs and LYs at a lower cost than Interferon, Natalizumab, Teriflunomide, and Alemtuzumab. However, Alemtuzumab had a higher cost but provided more QALYs and LYs than Ocrelizumab. Conclusions: Ocrelizumab was deemed cost-effective in the treatment of RRMS in Peru. It offered a favorable balance between cost and health outcomes, making it a compelling choice for RRMS management and resource allocation. The study's findings align with previous research highlighting the cost-effectiveness of Ocrelizumab in RRMS treatment across different healthcare systems. Limitations include the simplifications made in the model and the availability and accuracy of data sources used.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosisMultiple Sclerosis and Related Disorders, 2019
- El sobrepeso, la obesidad y la obesidad abdominal en la población adulta del PerúAnales de la Facultad de Medicina, 2019
- Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosisJournal of Medical Economics, 2017
- Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy2017
- Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling ApproachesPharmacoEconomics, 2014
- The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disabilityBrain, 2010
- Access to health care for people with multiple sclerosisMultiple Sclerosis Journal, 2007
- The natural history of multiple sclerosis: a geographically based study: 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosisBrain, 1999
- THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDYBrain, 1989
- Rating neurologic impairment in multiple sclerosisNeurology, 1983